研究目的
Investigating the risk factors for lymph node metastasis and the impact of adjuvant chemotherapy on ductal carcinoma in situ with microinvasion (DCISM).
研究成果
Younger patients with high-grade disease tend to have lymph node metastasis in DCISM. DCISM patients are unlikely to benefit from adjuvant chemotherapy. Further studies and randomized trials should be performed before any appropriate suggestion can be made.
研究不足
1. The SEER database records only the characteristics of the invasive component when both in situ and invasive components are present in a tumor. 2. Potentially significant clinicopathological factors, such as vascular invasion, surgical margin status, adjuvant endocrine therapy, and targeted therapy, are not provided by the SEER database. 3. HER2 status was not available before 2010 in the SEER database. 4. Due to the retrospective design of the study, there may be some inherent biases.
1：Experimental Design and Method Selection:
Retrieved DCISM data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registry database (1998–2013). Applied chi-squared tests and logistic regression models to investigate the potential risks of LN metastasis. Performed univariate and multivariate Cox proportional hazards regressions to estimate the prognostic factors of DCISM. Survival outcomes were estimated using the Kaplan–Meier method. A 1:1 propensity score matching was used to minimize potential bias.
2：3). Applied chi-squared tests and logistic regression models to investigate the potential risks of LN metastasis. Performed univariate and multivariate Cox proportional hazards regressions to estimate the prognostic factors of DCISM. Survival outcomes were estimated using the Kaplan–Meier method. A
2. Sample Selection and Data Sources: Data were extracted from the SEER program between 1998 and
3：Sample Selection and Data Sources:
2013. Included patients aged between 20 and 70 years old with microscopically confirmed stage T1mic. Excluded patients identified at autopsy, with death certificate only, no surgery treatment, or incomplete survival times. 3. List of Experimental Equipment and Materials: Not explicitly mentioned.
4：Included patients aged between 20 and 70 years old with microscopically confirmed stage T1mic. Excluded patients identified at autopsy, with death certificate only, no surgery treatment, or incomplete survival times. List of Experimental Equipment and Materials:
4. Experimental Procedures and Operational Workflow: Analyzed tumor demographics including grade, hormone status, and treatment characteristics. Defined patients with 1–5 LNs removed as sentinel lymph node biopsy (SLNB) and >5 LNs removed as axillary lymph node dissection (ALND).
5：Experimental Procedures and Operational Workflow:
5. Data Analysis Methods: All statistical analyses were performed using SPSS statistical software, version 22.0.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
